(Q40649226)

22 September 2017

title

Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools (English)

1 reference

22 September 2017

1

1 reference

22 September 2017

publication date

1 July 2016

1 reference

22 September 2017

1 reference

22 September 2017

volume

25

1 reference

22 September 2017

issue

8

1 reference

22 September 2017

page(s)

905-910

1 reference

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Pathogenesis of antiphospholipid syndrome: understanding the antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

The pathogenesis of the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

β(2) -Glycoprotein I: evolution, structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Cardiovascular disease in autoimmune rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

The antibacterial activity of peptides derived from human beta-2 glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

β₂-glycoprotein I: a novel component of innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

The dual role of innate immunity in antiphospholipid syndrome and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Update on the pathogenesis and treatment of the antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Introduction to special theme section: obesity and the rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316641772

21 January 2018

Identifiers

DOI

10.1177/0961203316641772

1 reference

22 September 2017

1 reference